ANDA 206550, held by Hikma. Flucytosine.
As of Nov 16, 2026, ANDA 206550 (Flucytosine), held by Hikma, was first approved by FDA on Oct 17, 2017, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 17, 2017 | Original application | Approved | None posted |
| Flucytosine250MG · capsule;oral | Flucytosine | Discontinued |
| Flucytosine500MG · capsule;oral | Flucytosine | Discontinued |
| Feb 18, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 18, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 18, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 17, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters